A single prior course of BCNU-cisplatin chemotherapy has a significant deleterious effect on mobilization kinetics of otherwise untreated patients

Bone Marrow Transplantation

Volumn 33, Issue 5, 2004, Pages 499-502

  Perez Calvo J ^a   Fernandez O ^a   Aristu, J J ^a   Aramendia, J M ^a   Rifon J ^a   Prosper, F ^a   Bendandi, M ^a   Rocha, E ^a   Martin Algarra, S ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

BCNU; CD34; Cisplatin; Glioma; Mobilization; Transplantation

Indexed keywords

CARMUSTINE; CD34 ANTIGEN; CISPLATIN; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; MELPHALAN; NITROSOUREA DERIVATIVE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; BLOOD TOXICITY; BONE MARROW DEPRESSION; BRAIN RADIATION; CANCER COMBINATION CHEMOTHERAPY; CELL KINETICS; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; GLIOBLASTOMA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKAPHERESIS; MALE; PRIORITY JOURNAL; STANDARD; STATISTICAL SIGNIFICANCE; STEM CELL MOBILIZATION; STEREOTAXIC SURGERY;

ADULT; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CARMUSTINE; CISPLATIN; COMBINED MODALITY THERAPY; GLIOMA; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; KINETICS; MIDDLE AGED;

EID: 18244410942     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704382     Document Type: Article

References (17)

1. Del Cañizo MC, López N, Vázquez L et al . Hematopoietic damage prior to PBSCT and its influence on hematopoietic recovery. Haematologica 1999; 84: 511-516.
2. Trainor KJ, Morley AA. Screening of cytotoxic drugs for residual bone marrow damage. J Natl Cancer Inst 1976; 57: 1237-1239.
3. Tricot G, Jagannath S, Vesole D et al. Peripheral blood stem cell transplants for multiple myeloma: Identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588-596.
4. Haas R, Möhle R, Frühauf S et al. Patient characteristics associated with successful mobilizing and autografting of peripheral bold progenitor cells in malignant lymphoma. Blood 1994; 83: 3787-3794.
5. Bensinger W, Appelbaum F, Rowley S et al. Factors that influence collection and engraftment of autologous peripheral blood stem cells. J Clin Oncol 1995; 13: 2547-2555.
6. De la Rubia J, Martínez C, Solano C et al. Administration of recombinant human granulocyte colony-stimulating factor to normal donors: Results of the Spanish National Donor Registry. Bone Marrow Transplant 1999; 24: 723-728.
7. Schmitz N, Dreger P, Suttorp M et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995; 85: 1666-1672.
8. Neben S, Hemman S, Montgomery M et al. Hematopoietic stem cell deficit of transplanted bone marrow previously exposed to cytotoxic agents. Exp Hematol 1993; 21: 156-162.
9. Drake M, Ranaghan L, Morris TCM et al. Analysis of the effect of prior therapy on progenitor cell yield: Use of a chemotherapy scoring system. Br J Haematol 1997; 98: 745-749.
10. Gandhi MK, Jestice K, Scott MA et al. The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. Bone Marrow Transplant 1999; 23: 9-13.
11. Clark RE, Brammer CG. Previous treatment predicts the efficiency of blood progenitor cell mobilization: Validation of a chemotherapy scoring system. Bone Marrow Transplant 1998; 22: 859-863.
12. Dreger P, Klöss M, Petersen B et al. Autologous progenitor cell transplantation: Previous exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood 1995; 86: 3970-3978.
13. Lee JL, Kim SB, Lee GW et al. Collection of peripheral blood progenitor cells: Analysis of factors predicting the yields. Transfusion Apher Sci 2003; 29: 29-31.
14. De Vita VT, Carbone PP, Owens Jr AH et al. Clinical trials with 1,3-bis(2-chloroethyl)-1-nitrosurea, NSC-409962. Cancer Res 1965; 25: 1876-1885.
15. Tew KD, Colvin M, Chabner BA. Alkylating agents. In: Chabner BA, Longo DL (eds). Cancer Chemotherapy and Biotherapy, 2nd edn. Lippincott-Raven Publishers: Philadelphia, 1996, pp 297-332.
16. Watts MJ, Sullivan AM, Jamieson E et al. Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: An analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma. J Clin Oncol 1997; 15: 535-546.
17. Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000; 18: 1360-1377.